2020 Consolidated Half Year Financial Report

Investor Centre

Investor News

Why Invest?

The FDA approval of Transcatheter Aortic Valve Replacement (TAVR) in the treatment of low-risk (younger patients) is driving rapid market expansion. Today we have

The Right Opportunity
to introduce a potential functional cure in the treatment of Aortic Stenosis where hemodynamics are reverted to normal pre-disease status and sustained for the life of the patient.

With TAVR now being the treatment of choice for Aortic Stenosis patients, coupled with existing Transcatheter Heart Valves failing as early as five to eight years after implantation, then now is

The Right Time
for a solution that Works Better & Lasts Longer.

At Anteris we bring

The Right Technology
to patients requiring a replacement valve. DurAVR™ heart valves address both the acute need in terms of superior hemodynamic profile, as well as chronic needs in their ability to sustain that profile longer, over the lifetime of the patient.

The inspiration for our DurAVR™ heart valves* stemmed from multiple conversations with interventional cardiologists, who reiterated that valve durability and repeat replacements were posing a large risk to patient health.

The proven benefits of our ADAPT® tissue paired with the unique design of DurAVR™ our 3D single-piece aortic valve, answers the need to

potentially deliver a functional cure
in the treatment of Aortic Stenosis, and provides a much-needed solution to the challenges facing heart surgeons today.

At Anteris we are committed in delivering durable solutions through our Better Science & Better Design that help healthcare professionals create life-changing outcomes for patients.

ASX Announcements

2020201920182017201620152014201320122011
    of 1
    ⚑ = Price Sensitive

    Financial Reports

    2020
    • 2020 Consolidated Half Year Financial Report
      View
    2019
    • 2019 Annual Report
      View
    • 2019 Consolidated Half Year Financial Report
      View
    2018
    • 2018 Annual Report
      View
    • 2018 Consolidated Half Year Financial Report
      View
    2017
    • 2017 Annual Report (Jul 16 - Jun 17)
      View
    • 2017 Annual Report (Jul 17 - Dec 17)
      View
    2016
    • 2016 Annual Report
      View
    • 2016 Consolidated Half Year Financial Report
      View
    2015
    • 2015 Annual Report
      View
    • 2015 Consolidated Half Year Financial Report
      View

    Research Reports

    • MST Access - Initiation of Coverage October 2020
      View
    • Bioshares July 2020 Report
      View
    • ABID June 2020 Report
      View
    • Bioshares June 2020 Report
      View
    • NDF Research - ADAPTing to market opportunities
      View

    Annual General Meetings

    14th May 2020
    Admedus 2020 AGM
    16th May 2019
    Admedus 2019 AGM
    23rd May 2018
    Admedus 2018 AGM
    16th Nov 2017
    Admedus 2017 AGM

    Share Registry

    Computershare Investor Services Pty Ltd

    Level 1, 200 Mary Street
    Brisbane, QLD 4000

    T 1300 850 505 (within Australia)
    T +61 3 9415 4000 (outside Australia)
    F 1800 783 447 (within Australia)
    F +61 3 9473 2555 (outside Australia)

    ComputerShare Investor Services manages our share registry. You can contact them for details about your holding here.

    Contact Us

    +1